CN110483501B - 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物 - Google Patents

作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物 Download PDF

Info

Publication number
CN110483501B
CN110483501B CN201910626474.XA CN201910626474A CN110483501B CN 110483501 B CN110483501 B CN 110483501B CN 201910626474 A CN201910626474 A CN 201910626474A CN 110483501 B CN110483501 B CN 110483501B
Authority
CN
China
Prior art keywords
compound
compounds
cancer
bcl
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910626474.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110483501A (zh
Inventor
S·王
J·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan Ann Arbor
Original Assignee
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan Ann Arbor filed Critical University of Michigan Ann Arbor
Publication of CN110483501A publication Critical patent/CN110483501A/zh
Application granted granted Critical
Publication of CN110483501B publication Critical patent/CN110483501B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
CN201910626474.XA 2016-08-05 2017-08-04 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物 Active CN110483501B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662371504P 2016-08-05 2016-08-05
US62/371,504 2016-08-05
US201762454101P 2017-02-03 2017-02-03
US62/454,101 2017-02-03
PCT/US2017/045428 WO2018027097A1 (en) 2016-08-05 2017-08-04 N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
CN201780035965.6A CN109311871B (zh) 2016-08-05 2017-08-04 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780035965.6A Division CN109311871B (zh) 2016-08-05 2017-08-04 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物

Publications (2)

Publication Number Publication Date
CN110483501A CN110483501A (zh) 2019-11-22
CN110483501B true CN110483501B (zh) 2022-07-01

Family

ID=59677319

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910626474.XA Active CN110483501B (zh) 2016-08-05 2017-08-04 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物
CN201780035965.6A Active CN109311871B (zh) 2016-08-05 2017-08-04 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780035965.6A Active CN109311871B (zh) 2016-08-05 2017-08-04 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物

Country Status (27)

Country Link
US (3) US10829488B2 (cg-RX-API-DMAC7.html)
EP (3) EP3569601B1 (cg-RX-API-DMAC7.html)
JP (2) JP6651180B2 (cg-RX-API-DMAC7.html)
KR (2) KR102376764B1 (cg-RX-API-DMAC7.html)
CN (2) CN110483501B (cg-RX-API-DMAC7.html)
AU (2) AU2017305508B2 (cg-RX-API-DMAC7.html)
CA (1) CA3031419C (cg-RX-API-DMAC7.html)
CY (1) CY1123859T1 (cg-RX-API-DMAC7.html)
DK (1) DK3494115T3 (cg-RX-API-DMAC7.html)
ES (1) ES2849959T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20202073T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053414T2 (cg-RX-API-DMAC7.html)
IL (2) IL264059B (cg-RX-API-DMAC7.html)
LT (1) LT3494115T (cg-RX-API-DMAC7.html)
MX (2) MX381588B (cg-RX-API-DMAC7.html)
MY (1) MY199409A (cg-RX-API-DMAC7.html)
PE (1) PE20190711A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019500231A1 (cg-RX-API-DMAC7.html)
PT (1) PT3494115T (cg-RX-API-DMAC7.html)
RS (1) RS61821B1 (cg-RX-API-DMAC7.html)
RU (2) RU2744358C2 (cg-RX-API-DMAC7.html)
SA (1) SA519401020B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201913643YA (cg-RX-API-DMAC7.html)
SI (1) SI3494115T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100025T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018027097A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201900240B (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156398A1 (en) * 2016-03-10 2017-09-14 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
CA3031419C (en) * 2016-08-05 2021-08-24 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
WO2018127130A1 (en) 2017-01-07 2018-07-12 Shanghai Fochon Pharmaceutical Co., Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
AU2018255621B2 (en) 2017-04-18 2022-03-10 Fochon Pharmaceuticals, Ltd. Apoptosis-inducing agents
SI3788042T1 (sl) 2018-04-29 2025-06-30 Beigene Switzerland Gmbh Zaviralci BCL-2
MX2020009759A (es) * 2018-07-31 2020-10-08 Ascentage Pharma Suzhou Co Ltd Efecto antitumoral sinergico de un inhibidor de bcl-2 combinado con rituximab y/o bendamustina o un inhibidor de bcl-2 combinado con chop.
JP7058345B2 (ja) * 2018-07-31 2022-04-21 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド Ｂｃｌ－２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用
CN110772521A (zh) * 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
WO2020024834A1 (en) * 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
AU2019385458A1 (en) * 2018-11-23 2021-01-07 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and use thereof
TWI770503B (zh) * 2019-05-13 2022-07-11 大陸商蘇州亞盛藥業有限公司 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
TW202114692A (zh) * 2019-07-02 2021-04-16 大陸商蘇州亞盛藥業有限公司 一種含有mTOR抑制劑的藥物組合及其應用
AU2020321068A1 (en) * 2019-07-31 2021-03-18 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
US12287338B2 (en) 2019-11-27 2025-04-29 Ascentage Pharma (Suzhou) Co., Ltd. Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
US12343352B2 (en) 2019-12-03 2025-07-01 Ascentage Pharma (Suzhou) Co., Ltd. N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors
US20220323465A1 (en) * 2019-12-04 2022-10-13 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
MX2022006631A (es) 2019-12-06 2022-09-07 Loxo Oncology Inc Dosificacion de un inhibidor de la tirosina cinasa de bruton.
CN113354636B (zh) * 2020-03-06 2022-08-09 苏州亚盛药业有限公司 N-(苯基磺酰基)苯甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
WO2021180040A1 (zh) * 2020-03-12 2021-09-16 南京明德新药研发有限公司 苯并五元环类化合物
TW202200574A (zh) 2020-04-15 2022-01-01 英屬開曼群島商百濟神州有限公司 Bcl-2抑制劑
WO2021227763A1 (en) * 2020-05-14 2021-11-18 Ascentage Pharma (Suzhou) Co., Ltd. Hplc analysis method for n- (phenylsulfonyl) benzamide compound
CN113880834B (zh) * 2020-07-01 2023-01-20 苏州亚盛药业有限公司 N-(苯基磺酰基)苯甲酰胺类化合物及其中间体的合成方法
CN111537654B (zh) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
CA3184959A1 (en) * 2020-07-10 2022-01-13 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Sulfonylbenzamide derivative and conjugate thereof, preparation method therefor and use thereof
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
JP2023539114A (ja) * 2020-08-21 2023-09-13 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド 全身性エリテマトーデスを治療する組成物及び方法
CN114073703B (zh) * 2020-08-21 2022-12-30 苏州亚盛药业有限公司 用于治疗非酒精性脂肪肝炎的组合物和方法
WO2022111558A1 (en) * 2020-11-25 2022-06-02 Ascentage Pharma (Suzhou) Co., Ltd. Solid dispersion, pharmaceutical preparations, preparation method, and application thereof
WO2022143602A1 (en) * 2020-12-28 2022-07-07 Ascentage Pharma (Suzhou) Co., Ltd. Methods of treating multiple sclerosis
CN114835704B (zh) * 2021-02-01 2023-10-27 苏州亚盛药业有限公司 作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物
EP4319800A1 (en) 2021-04-07 2024-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
EP4382126A4 (en) 2021-08-02 2025-07-30 Ascentage Pharma Suzhou Co Ltd PHARMACEUTICAL COMBINATION AND ITS USE
WO2023104043A1 (zh) * 2021-12-06 2023-06-15 杭州和正医药有限公司 一种抗凋亡蛋白bcl-2抑制剂、药物组合物及其应用
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用
EP4421075A1 (en) * 2023-02-27 2024-08-28 KRKA, d.d., Novo mesto Process for the preparation of venetoclax and intermediates used therein
CN121175043A (zh) 2023-03-03 2025-12-19 伊昂克图拉股份有限公司 用于治疗血液恶性肿瘤的罗吉诺利西布与bcl-2抑制剂的组合

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065824A2 (en) * 2008-12-04 2010-06-10 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011150016A1 (en) * 2010-05-26 2011-12-01 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN102448959A (zh) * 2009-05-26 2012-05-09 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN103153993A (zh) * 2010-05-26 2013-06-12 Abbvie公司 治疗癌症和免疫与自身免疫疾病的细胞程序死亡诱导药剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021343A (en) 1912-01-17 1912-03-26 M A N Mfg Company Locking-clamp.
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
CN101534904B (zh) 2006-09-05 2013-11-06 Abbvie公司 治疗血小板过量的bcl抑制剂
WO2008070663A2 (en) 2006-12-04 2008-06-12 Abbott Laboratories Companion diagnostic assays for cancer therapy
KR101692705B1 (ko) 2008-12-05 2017-01-04 애브비 인코포레이티드 암 및 면역 질환의 치료를 위한 Ｂｃｌ­２­선택적 아폽토시스-유도제로서의 설폰아미드 유도체
RU2538965C2 (ru) 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
WO2010093742A1 (en) 2009-02-11 2010-08-19 Abbott Laboratories Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers
CA3152557A1 (en) * 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UY33746A (es) 2010-11-23 2012-06-29 Abbott Lab Método de tratamiento que usa inhibidores selectivos de bcl-2
SI2643322T1 (en) * 2010-11-23 2018-01-31 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US10327687B2 (en) 2015-12-30 2019-06-25 Dexcom, Inc. System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile and baseline model of sensors
CA3031419C (en) 2016-08-05 2021-08-24 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065824A2 (en) * 2008-12-04 2010-06-10 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN102448959A (zh) * 2009-05-26 2012-05-09 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
WO2011150016A1 (en) * 2010-05-26 2011-12-01 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN103153993A (zh) * 2010-05-26 2013-06-12 Abbvie公司 治疗癌症和免疫与自身免疫疾病的细胞程序死亡诱导药剂

Also Published As

Publication number Publication date
JP7205903B2 (ja) 2023-01-17
KR20210107170A (ko) 2021-08-31
PT3494115T (pt) 2021-01-15
LT3494115T (lt) 2021-01-25
RU2020114660A3 (cg-RX-API-DMAC7.html) 2020-09-15
PE20190711A1 (es) 2019-05-17
CA3031419A1 (en) 2018-02-08
KR20190035710A (ko) 2019-04-03
AU2021202113A1 (en) 2021-05-06
JP2019527705A (ja) 2019-10-03
ZA201900240B (en) 2020-05-27
JP6651180B2 (ja) 2020-02-19
US20190315739A1 (en) 2019-10-17
US10221174B2 (en) 2019-03-05
IL282099A (en) 2021-05-31
IL264059B (en) 2021-05-31
SMT202100025T1 (it) 2021-03-15
US20180354950A1 (en) 2018-12-13
US20210002277A1 (en) 2021-01-07
SG11201900135YA (en) 2019-02-27
RU2020134802A (ru) 2022-04-25
MY199409A (en) 2023-10-25
NZ750100A (en) 2021-01-29
MX381588B (es) 2025-03-12
HRP20202073T1 (hr) 2021-02-19
RU2020114660A (ru) 2020-06-19
SA519401020B1 (ar) 2022-03-16
IL264059A (en) 2019-01-31
CN109311871B (zh) 2020-02-28
CY1123859T1 (el) 2022-05-27
JP2020007311A (ja) 2020-01-16
EP3569601A2 (en) 2019-11-20
EP4129999A1 (en) 2023-02-08
RU2744358C2 (ru) 2021-03-05
CA3031419C (en) 2021-08-24
AU2017305508B2 (en) 2021-01-07
DK3494115T3 (da) 2021-01-18
EP3569601B1 (en) 2022-06-22
BR112019001666A2 (pt) 2019-05-28
CN110483501A (zh) 2019-11-22
RU2722560C1 (ru) 2020-06-01
EP3494115A1 (en) 2019-06-12
EP3494115B1 (en) 2020-10-21
ZA201908466B (en) 2020-05-27
WO2018027097A1 (en) 2018-02-08
AU2017305508A1 (en) 2019-02-07
PH12019500231A1 (en) 2019-07-29
KR102376764B1 (ko) 2022-03-18
US10829488B2 (en) 2020-11-10
SI3494115T1 (sl) 2021-02-26
SG10201913643YA (en) 2020-03-30
MX2019001391A (es) 2019-06-06
EP3569601A3 (en) 2019-11-27
MX2020013014A (es) 2021-02-22
ES2849959T3 (es) 2021-08-24
KR102429704B1 (ko) 2022-08-04
HUE053414T2 (hu) 2021-06-28
CN109311871A (zh) 2019-02-05
US11718613B2 (en) 2023-08-08
RS61821B1 (sr) 2021-06-30
IL282099B (en) 2022-03-01
AU2021202113B2 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
CN110483501B (zh) 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物
JP2020519667A (ja) ＬＳＤ−１インヒビターとしてのピロロ〔２，３−ｃ〕ピリジン及び関連類似体
CN110294750A (zh) 作为alk抑制剂的5,6-二氢-11h-吲哚并[2,3-b]喹啉-11-酮化合物
RU2831159C2 (ru) N-(фенилсульфонил) бензамиды и родственные соединения в качестве ингибиторов bcl-2
HK40001439B (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40001439A (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
JP2024504542A (ja) Ｂｃｌ－２阻害剤としてのスルホニルベンズアミド誘導体
RU2831159C9 (ru) N-(фенилсульфонил) бензамиды и родственные соединения в качестве ингибиторов bcl-2
KR20230065986A (ko) Bcl-2 억제제로서의 헤테로시클릭 화합물
BR112019001666B1 (pt) Compostos de n-(fenilsulfonil)benzamidas e sais e solvatos dos mesmos, composições farmacêuticas e seus usos no tratamento de doenças, distúrbios ou afecções através da inibição de bcl-2
HK40019323A (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40019323B (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40001725A (en) N-(phenylsulfonyl)benzamide derivatives as bcl-2 inhibitors
HK40001725B (en) N-(phenylsulfonyl)benzamide derivatives as bcl-2 inhibitors
NZ750100B2 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40012150A (en) 5,6-dihydro-11h-indolo[2,3-b]quinolin-11-one compounds as alk inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant